Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 212 pages

Showing 201 - 212


prostate cancer

Increased Radiation Dose With Hypofractionated vs Conventional Radiation Therapy Does Not Improve Biochemical/Clinical Failure Rate in Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Alan Pollack, MD, PhD, of University of Miami Miller School of Medicine, and colleagues compared escalated radiation dose using hypofractionated vs conventional fractionation intensity-modulated radiation therapy in men with favorable-...

prostate cancer
issues in oncology

LAT Inhibition May Be a New Therapeutic Option for Metastatic Castration-Resistant Prostate Cancer

L-type amino acid transporters (LAT) uptake neutral amino acids including L-leucine into cells, stimulating mTOR complex 1 (mTORC1) signaling and protein synthesis. LAT1 and LAT3 are overexpressed at different stages of prostate cancer and are involved in increasing nutrients and stimulating cell...

prostate cancer
supportive care

No Additional Benefit of Venlafaxine or Soy Protein vs Placebo on Hot Flashes in Men With Prostate Cancer

Hot flashes occur in approximately 80% of androgen-deprived men. In a randomized study reported in the Journal of Clinical Oncology by Mara Z. Vitolins, DrPH, MPH, RD, of Wake Forest School of Medicine, and colleagues, neither venlafaxine nor soy protein—both of which have been used to...

prostate cancer

Long-Term Follow-up Indicates Increased Telomere Length With Lifestyle Change in Men With Low-Risk Prostate Cancer

Short telomere length in peripheral blood mononuclear cells is associated with aging and such age-related diseases as cancer, stroke, vascular dementia, cardiovascular disease, obesity, osteoporosis, and diabetes. Telomere attrition is considered a potential mechanism in triggering the chromosomal...

prostate cancer

Denosumab Increases Bone Metastasis-Free Survival According to PSA Doubling Time in Men With Nonmetastatic Castration-Resistant Prostate Cancer

In a recently reported phase III trial, denosumab (Xgeva) significantly increased bone metastasis–free survival and delayed time to first bone metastasis but did not improve overall survival compared with placebo in men with nonmetastatic castration-resistant prostate cancer and baseline...

prostate cancer

Night or Rotating Shift Work Associated With Increased Risk for High PSA

Some data support an association between circadian disruption and prostate cancer. In a study reported in Journal of the National Cancer Institute, Erin E. Flynn-Evans, PhD, of the Division of Sleep Medicine at Brigham and Women’s Hospital, and colleagues assessed the association between...

issues in oncology
prostate cancer

Finasteride Reduces Risk of Low-Grade Prostate Cancer With No Impact on Long-Term Survival

In the Prostate Cancer Prevention Trial (PCPT), initially reported in 2003, finasteride significantly reduced the risk of prostate cancer by 24.8% but was associated with a relative 26.9% increase in risk of high-grade disease compared with placebo. In a study reported in The New England Journal of ...

prostate cancer

Metformin Use Reduces All-Cause and Prostate Cancer–Specific Mortality in Men With Diabetes

In a study reported in Journal of Clinical Oncology, David Margel, MD, PhD, of University of Toronto, and colleagues examined the effect of duration of antidiabetic medication exposure after prostate cancer diagnosis on all-cause and prostate cancer–specific mortality in men with diabetes....

prostate cancer
issues in oncology

Swedish Initiative Results in Significant Reduction in Inappropriate Prostate Cancer Imaging

A number of initiatives have been implemented to encourage reduction of inappropriate use of imaging to stage incident prostate cancer. Since 2000, the National Prostate Cancer Register (NPCR) of Sweden has led an effort to decrease national rates of inappropriate prostate cancer imaging by...

prostate cancer

No Benefit of Adding Atrasentan to Docetaxel in Advanced Castration-resistant Prostate Cancer

The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer, and the investigational endothelin receptor antagonist atrasentan has shown activity in prostate cancer. In the SWOG S0421 trial reported in Lancet Oncology by David I. Quinn, FRACP, of...

prostate cancer

Radium-223 Dichloride Prolongs Overall Survival in Men with Metastatic Prostate Cancer in Phase III ALSYMPCA Trial

In a trial (ALSYMPCA) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, United Kingdom, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and...

prostate cancer

Addition of Aflibercept to Docetaxel/Prednisone Does Not Improve Overall Survival in Men with Metastatic Castration-resistant Prostate Cancer

In a phase III double-blind study (VENICE trial) reported in Lancet Oncology, Ian F. Tannock, DSc, of Princess Margaret Cancer Centre in Toronto, and colleagues evaluated the addition of the antiangiogenic agent aflibercept (Zaltrap) to standard docetaxel/prednisone therapy in patients with...

Advertisement

Advertisement



Advertisement